- The exact cause of Parkinson’s Disease Remains Unknown; However, Knowers Know The Pink1 gene.
- A New Study for the First Time Explains What Human Pink1 Like and How is Activated looks.
- Believe Refrillas Best Findings May Help One Day Lead to New Treatment Options for Parkinson’s Disease.
Researchers Estimate That About 10 Million People Globally Live Withinson’s Disease – A Neurological Condition That Affects Movement.
While The Exact Cause of Parkinson’s Disease is Still Unknown, Past Studies Show That A Combination of Both Environmental and Genetic Factors contribute to the condition.
For Instance, Scientists have discovered that having certain genes may increased to Perso’s Risk for Developing Parkinson’s Disease, Such as a mutation in the Pink1 (Ptenudu Putative Kinase 1) Gene.
Now, New Study Recently Published in the Journal Science for the first time explains What Human Pink1 Like and How is Activated looks.
Believe Refrillas Best Findings May Help One Day Lead to New Treatment Options for Parkinson’s Disease.
What Does Pink1 do in the body?
Pink1 Plays an important role in the body as the protein it Expressses Helps Protect Mithochondria – The Cellular Energy Sources – From Harm, and Leads Their Remainval From The Body When They Do Become Damaged Over Time.
“(The) Pink1 (Protein) Acts as a Beacon for Damaged Mithochondria, Famously Known as the ‘Powerhouse of the Cell’,” Sylvie Callegari, phd, senior Research offer in the ubiquitin signalling division at the walter and eliza hall institute of Medical Research in Australia and correspondent author of this study aw Medical News Today.
“Pink1 sensses this Damage and docks to the surface of mithochondria. Elevenious on the mithochondrial surface, Pink1 Becomes Active and Seeks out a Small Protein Known As
“When Damaged Mithochondria Are Not Clened Up, They Release Toxens, Which Kill Cells,” She continues. “Brain Cells, Such as Neurons, which requires Lot of Energy and Have a Lot of Mithochondria Are privately sensitive to mythochondrial toxicity and are more Likely to die. The Death of Neuronal Cells in the Brain Is What Causes Parkinson’s Disease.”
Mutated Pink1 Leads to Neuronal Cell Death
Callegari Said That Up Until Now, One of the Main Obstacles That Has Prevented Researchers from Seeing What Pink1 Like Like was like there is not see much Pink1 in the Cell.
“Until Now, Scientists Had Been Studying Insect Pink1 Becouse It is positive to produce it in long amount, and by Visualizing Insect Pink1, We Were Uble to Decipher How it Can Be Activated,” She Explained.
“However, We Were Never Uble to See How Pink1 Docks to the Mithochondrial Surface, which is the Important Step that precedes ITS Activation. To get around this problem, we used Vary Large Amounts of Cells (Nearly 10L) to get angouh human pink1 that we could Than uses for visualization using
Callegari and her team discovered there are Four Main Steps to How Pink1 Works: Damage Mithochondrial Sensing, Attaching to The Damaged Mithochondria, Tagging Ubiquitin, and The Ubiquitin Links to A Protein Calleed Parkin to “Recycle” The Injurate Mithochondria.
“Pink1 is Special Because it can alter the ubiquitin tag by placing an addition marker on it – It basicly tags the tag,” Callegari Said. “This Alteration is a Vry Specific Signal that Initiates The Province of the Entire Mithochondria.”
How Pink1 Causes Parkinson’s
“When Pink1 is mutated, it cannot performer its signaling function, and so mithochondria are not effffively Cleaned Up. Defective Mithochondria Are toxic to Cells, resulting in Cell Death. The Death of Neuronal Cells in the Brain Causes Parkinson’s Disease.”
– Sylvie Callegari, PHD
‘Big Leap Closer’ to New Parkinson’s Disease Therapies
Callegari Believes The Findings Bring Us A Big Leap Closer To Developing Therapies For Parkinson’s Disease.
“Ideally, We want to design a Drug That Makes Pink1 More Active, But Without The Ability to See Pink1, It Is Vary Hard To Develop a Drug to Do This,” She Explanred. “Now that we can see pink1, we have the Blueprint that we need to improve us activity.”
“There are Currently Sub Drugs in the Pipeline which are Believed To increase the activity of pink1, but without ever seeing where or how tohele drarugs interact with pink1, we don’t have a complete Underestanding of How they Drugs in Association with Pink1 To Understand How They Work.
– Sylvie Callegari, PHD
New Targeted Therapies Based Pink1
MNT Spoke with Daniel Truong, MD, Neurologist and Medical Director of the Truong Neuroscience Institute at Memorialcare Orange Coast Medical Center in Fountain Valley, CA, and Editor-in-Chief of the Journal of Clinical Parkinsonism and Related Disorders, About This Study.
“As a Physician Who Treats Patients Withinson’s Disease, The Recent Ecucidation of the Human Pink1 Protein Structure Bound to Mithochondria is a significant and finding development,” Truong Commented.
“Mutations in the Pink1 Gene Have Been Linked to Early-Oset Parkinson’s Disease. By resolving the structure of pink1, Rebuided deeper Insights into the function and how its dysfunction can lead to neurodegeneration, ”I have added.
“Underestanding the Structural Configuration of Pink1 Will Open Avenues for Developing Targeted Therapies Aimed at Moduling its Activity. Underestanding of the Structural Blueprint of Pink1, Pharmaceutical Research Can Focus On Designing Molecules That Interact Exce precise relays with This Protein Leading to More Effective Treatments With Fewer Side Effects.
– Daniel Truong, MD
Translating Findings into Treatment Will Requirement More Research
MNT Also Spoke with Two Neurologists from Hackensack Meridian in New Jersey About This Research.
Rocco Dipaola, MD, Neurologist and Movement Disorder Specialist at Hackensack Meridian Neuroscience Institute at the Jersey Shore University Medical Center CommeroDo The That This Study is Another Positive Step in Uncovering and Underestanding The Mechanisms In Hereditary Forms of Parkinsonism.
“It is important to continue to look for new ways to treat parkinson’s disease, as currente therapies have their limitations, primarily addressing
UMER AKBAR, MD, Neurologist and Director of the Movement Disorder Center in the Department of Neurology and Hackensack Meridian Neuroscience Institute at Hackensack University Medical Center, Said That While This Discovery Provides Crucial Foundational Knowledge Effective Treatment Will require Further Research.
“Drug Development is a long and complex process, and many promising draw candidates fail in clinical trials. However, This Discovery Undoubtedly Removes to Major Obstacle and significantly increase Future Research and Drug Development Efforts. “
– Uumer Akbar, MD
